Pharmaceutical - Novo Nordisk, Global

Filter

Current filters:

Novo NordiskGlobal

Popular Filters

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

08-10-2014

Ultra-rapid formulations of the currently marketed rapid-acting insulin analogs have the clear potential…

AdociaBioChaperoneDiabetesFIAspGlobalMarkets & MarketingNovo NordiskPharmaceuticalResearch

Existing diabetes drug Victoza could be effective treatment for world’s obese

Existing diabetes drug Victoza could be effective treatment for world’s obese

06-08-2014

Pharmaceutical companies are racing to find a new form of obesity drug as patient numbers spiral and…

Anti-diabetic drugsDiabetesGastro-intestinalsGlobalMarkets & MarketingNovo NordiskPeptide hormonesPharmaceuticalVictoza

Global insulin market set to reach $32.24 billion in 2019

Global insulin market set to reach $32.24 billion in 2019

28-07-2014

The global insulin market was valued at $19.99 billion in 2012 and is expected to expand at a compound…

AfrezzaChinaDiabetesEli LillyGlobalInsulinLY2605541MannKindMarkets & MarketingMerck & CoMK-1293NN1218Novo NordiskPharmaceutical

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review

03-12-2012

Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

Global diabetes drugs market led by Novo Nordisk and Sanofi

14-11-2012

The global diabetes drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

DiabetesGlobalMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Back to top